GlassScriptPhysician profile
Ravinder K Kurl
NPI 1386737666
$2,226.98
in general payments reported to CMS, 2019-2025
15 companies · $544 in 2025
The $544 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $178 · 2021: $224 · 2022: $385 · 2023: $324 · 2024: $372 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,156 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,155.76 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,027.33 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $206.19 | 2022-2024 | |
| Astellas Pharma US INC | $197.79 | 2019-2023 | |
| Novo Nordisk INC | $173.11 | 2019-2023 | Ozempic, Rybelsus |
| Radius Health, INC. | $111.12 | 2025 | Tymlos |
| Abbott Laboratories | $93.81 | 2022-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $79.37 | 2021-2023 | Trelegy Ellipta |
| Exact Sciences Corporation | $78.73 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Nevro Corp. | $56.80 | 2024 | Senza |
| Amgen INC. | $56.42 | 2024-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $53.27 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $42.27 | 2020-2022 | |
| Pfizer INC. | $19.33 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.46 | 2022 | |
| Grifols USA, LLC | $13.98 | 2024 | Prolastin-C Liquid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravinder Kurl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.